LENSAR Inc (LNSR)

Healthcare Medical Devices

5.00 $

-3.1% vs. previous close

Closing price · As of: 31. Jul 2026

Add to watchlist

Stock Watch

Stock Watch will tell you what changes at LENSAR Inc.

Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.

Appears in These Scanners

This stock currently matches 1 of our scanner strategies — each hit links to the scanner.

Momentum & Trend

Power Trend

Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners

Basics

Market Cap

0.1$B

Shares Outstanding

12Mio.

Float

70.6%

Beta

0.9

Performance

Perf. 1M

-4.70%

Perf. 3M

-5.80%

Perf. 6M

-52.40%

YTD Performance (%)

-50.80%

52-Week-High Distance

-54.4%

Perf. 1Y

-50.49%

Perf. 3Y

43.00%

Perf. 5Y

-27.08%

Valuation

P/E

–

Forward P/E

0.0

PEG

–

P/B

5.3

P/S

1.1

EV/EBITDA

-1.0

Price/FCF

–

Profitability

Gross Margin

45.7%

EBIT Margin

–

Net Margin

50.9%

Return on Equity

36.3%

Return on Assets

-22.6%

Balance Sheet & Safety

Equity Ratio

–

Debt/Equity

0.1

Altman Z″

2.34

Piotroski

6 out of 9

Growth

Sales Growth Last Quarter

-5.20%

EPS Growth Last Quarter

0.00%

Sales Growth (Year)

9.24%

Forward Sales Growth

21.02%

Forward EPS Growth

-787.50%

Dividend

This stock currently pays no dividend.

Quality & Screener

Stage

RS Rating

EPS Rating

Piotroski

6 out of 9

Fundamental Rating

C (50 out of 100)

Altman Z″

2.34

AI Rating

–

Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built

Analysts & Price Target

Current Price 5.00 $

Price Target (average) 8.50 $

The price target sits 70.0% above the current price.

Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.

Next Reporting Date

6. Aug 2026 · before the open · Q2 2026

Expected Earnings per Share: -0.27 $

Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.

From To Indexed

Click the chart or tab into it, then use ← and → to step through the periods.

None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.

These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.

The figures could not be loaded right now.

Sales Per Quarter ($M)

Source: fundamental data

Compare with other stocks →

Quarterly Figures

Quarterly Figures
Quarter	EPS (Earnings Per Share)	EPS YoY (%)	Sales ($M)	Sales YoY (%)	Net Margin (%)	OCF ($M)	FCF ($M)
2024: Q4	-1.52	–	17	38.20	-111.80	4	4
2025: Q1	-2.23	–	14	33.70	-193.10	-7	-7
2025: Q2	-0.14	–	14	10.30	-12.70	-5	-5
2025: Q3	-0.30	–	14	5.70	-25.90	-4	-4
2025: Q4	-0.12	–	16	-4.20	-9.10	1	1
2026: Q1	2.96	–	13	-5.20	270.60	-4	-4

What Do These Terms Mean?

EPS (Earnings Per Share):: Quarterly profit divided by the total share count — how much of the profit works out to a single share.
YoY (Year over Year):: Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
Sales:: All revenue for the quarter, before any costs are deducted — the top line of the income statement.
Net Margin:: What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
OCF (Operating Cash Flow):: The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
FCF (Free Cash Flow):: Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.

About the Company

LENSAR, Inc., ein Medizintechnikunternehmen in der Vermarktungsphase, konzentriert sich auf Entwurf, Entwicklung und Vermarktung von Lasersystemen zur Behandlung von Katarakten und zum Management von vorbestehendem oder chirurgisch induziertem Hornhautastigmatismus in den USA, Europa, Asien, Südkorea und international.

Employees	150
Headquarters	Orlando, FL
Website	lensar.com
IPO Date	2. Oct 2020

Management

Management
Name	Title	Birth Year
Nicholas T. Curtis	President, CEO & Director	1956
Alan B. Connaughton	Chief Operating Officer	1972
Michael A. Rossi	Interim CFO & Principal Financial Officer and Secretary	1974
Kendra W. Wong	Principal Accounting Officer	1980

Executives per the latest required filings; titles kept in their original language. Source: fundamental data.

Chart

Interactive price chart (TradingView).

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.